2025年美国临床肿瘤学会（ASCO）年会将于2025年5月30日至6月3日（比北京时间晚13小时）在美国芝加哥举行。目前，ASCO官网已公布了本次会议的日程和摘要题目。【肿瘤资讯】整理了口头报告专场（Oral Abstract Session）、临床科学研讨会（Clinical Science Symposium）、摘要速递专场（Rapid Oral Abstract Session）、中枢神经系统肿瘤（Central Nervous System Tumors）的乳腺肿瘤研究，与读者分享。
Rapid Oral Abstract Session
转移性乳腺癌
Breast Cancer—Metastatic
专场时间：2025年5月30日 14:45 –16:15（本文均为美国当地时间）
专场主席：Jose G. Bazan, MD City of Hope Comprehensive Cancer Center；Yara Abdou, MD Division of Oncology, Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill
专场地点：Hall D2 | Live Stream
摘要号：1036
HER2阳性转移性乳腺癌接受抗体偶联药物治疗的种族/民族差异：TriNetX真实世界证据研究
Racial and ethnic disparities in clinical outcomes of HER2-positive metastatic breast cancer treated with antibody-drug conjugates: A TriNetX real-world evidence study.
讲者: Zunairah Shah, MD | Roswell Park Comprehensive Cancer Center
摘要号：1014
使用人工智能辅助软件进行 HER2 低表达和 HER2 超低表达免疫组化（IHC）判读培训，提高病理诊断准确性并扩大HER2靶向治疗患者人群
Use of artificial intelligence–assistance software for HER2-low and HER2-ultralow IHC interpretation training to improve diagnostic accuracy of pathologists and expand patients' eligibility for HER2-targeted treatment.
讲者: Marina De Brot, MD, PhD | A.C. Camargo Cancer Center
摘要号：1015
德曲妥珠单抗相关间质性肺病后的治疗再挑战：一项多机构队列研究
Treatment rechallenge after trastuzumab-deruxtecan–related interstitial lung disease: A multi-institution cohort study.
讲者:Hope S. Rugo, MD, FASCO | University of California, San Francisco Helen Diller Family Comprehensive Cancer Center
摘要号：1016
瑞波西利联合曲妥珠单抗及内分泌治疗 HR+/HER2+ 晚期乳腺癌患者的 Ib 和 II 期研究（KCSG BR 18-2 MINI）
Phase IB and II study of ribociclib with trastuzumab plus endocrine therapy in HR+/HER2+ advanced breast cancer patients: Korean Cancer Study Group BR 18-2 MINI trial.
讲者: Joohyuk Sohn, MD, PhD | Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine
摘要号：1017
HER2-ADC SHR-A1811用于HER2阳性乳腺癌脑转移患者：REIN试验最新结果
HER2-ADC trastuzumab rezetecan (SHR-A1811) in HER2-positive breast cancer with brain metastases: Update results from REIN trial.
讲者: 闫敏, MD | 河南省肿瘤医院
摘要号：1018
一项阿得贝利单抗联合贝伐珠单抗以及顺铂/卡铂用于脑转移三阴性乳腺癌（TNBC）患者的II期临床研究
A phase II clinical study of adebrelimab and bevacizumab combined with cisplatin/carboplatin in triple-negative breast cancer patients with brain metastases.
讲者: 李婷, MD | 复旦大学附属肿瘤医院
摘要号：1019
芦康沙妥珠单抗一线治疗不可切除的局部晚期/转移性三阴性乳腺癌（a/mTNBC）：II 期 OptiTROP - Breast05 研究初步结果
Sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from the phase II OptiTROP-Breast05 study.
讲者: 殷咏梅, MD, PhD | 江苏省人民医院
摘要号：1020
PF-07248144（一种首创的赖氨酸乙酰转移酶 6[KAT6]抑制剂）在 ER+/HER2-转移性乳腺癌患者中的剂量优化：1 期研究结果以支持推荐的 3 期剂量（RP3D）
Dose optimization of PF-07248144, a first-in-class KAT6 inhibitor, in patients (pts) with ER+/HER2− metastatic breast cancer (mBC): Results from phase 1 study to support the recommended phase 3 dose (RP3D).
讲者: Patricia LoRusso, PhD, FASCO, DO | Yale School of Medicine
摘要号：1021
KM-10A/KCSG BR18-13：曲妥珠单抗联合gedatolisib用于2种及以上HER2导向化疗后进展的HER2阳性转移性乳腺癌
Phase II study of trastuzumab-pkrb plus gedatolisib in patients with HER2-positive metastatic breast cancer who progressed after 2 or more HER2-directed chemotherapies (KM-10A/KCSG BR18-13).
讲者: KyongHwa Park, MD, PhD | Division of Oncology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine
Rapid Oral Abstract Session
乳腺癌-局部/区域/辅助
Breast Cancer—Local/Regional/Adjuvant
专场时间：2025年6月1日 08:00-09:30
专场主席：Eileen Connolly, MD, PhD Columbia University Irving Medical Center；Matteo Lambertini, MD U.O. Clinical Oncology, IRCCS Ospedale Policlinico San Martino, University of Genova
专场地点：Hall B1 | Live Stream
摘要号：LBA509
NRG-BR003 III期试验：多柔比星+环磷酰胺序贯周疗紫杉醇±卡铂治疗淋巴结阳性/高危淋巴结阴性三阴性乳腺癌的随机研究
NRG-BR003: A randomized phase III trial comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative TNBC.
讲者:Vicente Valero, MD | The University of Texas MD Anderson Cancer Center
摘要号：510
评估早期TNBC同源重组缺陷（HRD）患者新辅助奥拉帕利/卡铂对比多西他赛/表柔比星/环磷酰胺（TAC）疗效和安全性的前瞻性随机 2 期试验：ABCSG 45 试验的初步结果
Prospective randomized phase II trial to assess the efficacy and safety of neo-adjuvant olaparib/carboplatin (OC) in comparison to docetaxel/epirubicin/cyclophosphamide (TAC) in patients with early triple-negative breast cancer (TNBC) with homologous recombination deficiency (HRD): Primary results from the ABCSG 45 trial.
讲者: Christian F. Singer, MD, MPH | Department of Obstetrics and Gynecology and Center for Breast Health, Comprehensive Cancer Center, Medical University of Vienna and Austrian Breast and Colorectal Cancer Study Group
摘要号：511
早期TNBC患者以疗效为导向的新辅助戈沙妥珠单抗和帕博利珠单抗（SG/P）治疗的 2 期研究：NeoSTAR 试验结果
A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial.
讲者: Rachel Occhiogrosso Abelman, MD | Massachusetts General Hospital Cancer Center, Harvard Medical School
摘要号：512
Promise 研究：绝经后导管原位癌女性术前 CE/BZA 对比安慰剂的随机临床试验
The Promise study: A presurgical randomized clinical trial of CE/BZA vs placebo in postmenopausal women with ductal carcinoma in situ
讲者: Swati Kulkarni, MD | Northwestern University Feinberg School of Medicine
摘要号：513
WinPro试验：一项针对绝经后早期HR+乳腺癌患者内分泌治疗±孕酮的机会窗研究
The WinPro trial: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer.
讲者: Lucy Haggstrom, MD | St Vincent's Hospital Sydney and University of New South Wales
摘要号：514
法国多中心、随机 SHARE 试验比较绝经后早期低危乳腺癌女性全乳照射与加速部分乳腺照射的早期结果：毒性和美容结局分析
Early results of the French multicenter, randomized SHARE trial comparing whole breast irradiation versus accelerated partial breast irradiation in postmenopausal women with early-stage low risk breast cancer: Analysis of toxicity and cosmetic outcomes.
讲者:Yazid Belkacemi | AP-HP, Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital, University of Paris Est Creteil (UPEC)
摘要号：515
达尔西利联合内分泌治疗用于HR+/HER2-早期乳腺癌辅助治疗：随机、III期DAWNA-A试验
Dalpiciclib (Dalp) plus endocrine therapy (ET) as adjuvant treatment for HR+/HER2– early breast cancer (BC): The randomized, phase 3, DAWNA-A trial.
讲者: 邵志敏 | 复旦大学附属肿瘤医院
摘要号：516
NATALEE 研究中瑞波西利+非甾体芳香化酶抑制剂（NSAI）的疗效和安全性：按绝经状态和年龄分析
Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in NATALEE: Analysis across menopausal status and age.
讲者: Kevin Kalinsky, MD, FASCO, MS | Winship Cancer Institute at Emory University
摘要号：517
TRADE 研究：一项评估早期 HR+/HER2- 乳腺癌患者阿贝西利剂量递增耐受性的 2 期试验
The TRADE study: A phase 2 trial to assess the tolerability of abemaciclib dose escalation in early-stage HR+/HER2- breast cancer.
讲者: Erica L. Mayer, MD, FASCO, MPH | Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
Oral Abstract Session
转移性乳腺癌
Breast Cancer—Metastatic
专场时间：2025年5月31日 13:15 – 16:15
专场主席：Gregory A. Vidal, MD, PhD West Cancer Center and Research Institute and University of Tennessee Health Sciences Center；Sharon H. Giordano, MD, FASCO The University of Texas MD Anderson Cancer Center
专场地点：Hall B1 | Live Stream
摘要号：LBA1000
Vepdegestrant（一种蛋白水解靶向嵌合体[PROTAC]雌激素受体降解剂）对比氟维司群治疗ER+/HER2-晚期乳腺癌的全球随机3期VERITAC-2研究结果
Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study.
讲者: Erika P. Hamilton, MD | Breast Cancer Research Program, Sarah Cannon Research Institute
摘要号：1001
Imlunestrant单药或联合阿贝西利治疗ER+/HER2-晚期乳腺癌患者：EMBER-3 III期试验患者报告结局
Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator’s choice standard endocrine therapy, or imlunestrant + abemaciclib: Results from the phase III EMBER-3 trial.
讲者: Giuseppe Curigliano, MD, PhD | Istituto Europeo di Oncologia, IRCCS, University of Milano
摘要号：1003
INAVO120 Ⅲ期试验最终总生存期分析：一线Inavolisib/安慰剂+哌柏西利+氟维司群治疗PIK3CA突变HR+/HER2-内分泌耐药晚期乳腺癌
INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC).
讲者: Nicholas C. Turner, MD, PhD | Royal Marsden Hospital and Institute of Cancer
摘要号：1004
Inavolisib单药或联合内分泌治疗±哌柏西利治疗PIK3CA突变HR+/HER2-局部晚期/转移性乳腺癌的I/Ib期研究：糖尿病前期/肥胖患者的高血糖分析
Phase I/Ib study of inavolisib (INAVO) alone and in combination with endocrine therapy ± palbociclib (PALBO) in patients (pts) with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced/metastatic breast cancer (HR+, HER2– LA/mBC): Analysis of hyperglycemia (HG) in prediabetic/obese pts.
讲者: Mafalda Oliveira, MD, PhD | Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO)
摘要号：LBA1005
CCTG/BCT MA.40/FINER研究：氟维司群联合Ipatasertib用于CDK4/6抑制剂和芳香酶抑制剂一线治疗后进展的ER+晚期乳腺癌的双盲III期试验
A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER-2 negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor: The CCTG/BCT MA.40/FINER study (NCT04650581).
讲者: Stephen K. L. Chia, MD, FRCPC | BC Cancer Agency
摘要号：1007
口服紫杉醇（DHP107）对比静脉注射紫杉醇治疗 HER2 阴性复发或转移性乳腺癌的 3 期试验：一项多国优化试验（NCT03315364）的初步分析
Phase III of oral paclitaxel (DHP107) vs intravenous paclitaxel in HER2-negative recurrent or metastatic breast cancer (mBC): Primary analysis of a multinational optimal trial (NCT03315364).
讲者: Sung-Bae Kim, MD | Asan Medical Center, University of Ulsan College of Medicine
摘要号：1013
DESTINY-Breast06探索性生物标志物分析：德曲妥珠单抗对比化疗治疗HER2低/超低表达HR+转移性乳腺癌
Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in HER2-low/ultralow, hormone receptor–positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06).
讲者: Rebecca Alexandra Dent, MD, FASCO |National Cancer Centre Singapore
Oral Abstract Session
乳腺癌-局部/区域/辅助
Breast Cancer—Local/Regional/Adjuvant
专场时间：2025年6月2日 15:00 – 18:00
专场主席：Oluwadamilola Motunrayo Fayanju, MD Perelman School of Medicine, University of Pennsylvania ；Kari Braun Wisinski, MD
University of Wisconsin Carbone Cancer Center
专场地点：Hall B1 | Live Stream
摘要号：LBA500
降阶紫杉类药物联合曲妥珠单抗和帕妥珠单抗±卡铂新辅助治疗HER2阳性早期乳腺癌（neoCARHP）：一项多中心、开放标签、随机、3期试验
De-escalated neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2-positive early breast cancer (neoCARHP): A multicentre, open-label, randomised, phase 3 trial.
讲者: 王坤 MD, PhD | 广东省人民医院
摘要号：501
紫杉类、曲妥珠单抗和帕妥珠单抗（THP）治疗的 Ⅱ/Ⅲ期 HER2+ 乳腺癌中，根据临床病理变量和 HER2DX 基因检测预测病理完全缓解（pCR）：EA1181/CompassHER2 pCR 试验的二次结果
Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): Secondary results from the EA1181/CompassHER2 pCR trial.
讲者: Nadine M. Tung, MD, FASCO | Beth Israel Deaconess Medical Center
摘要号：502
HER2+早期乳腺癌降阶梯新辅助治疗后生存预测：三项WSG试验的汇总分析
Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trials.
讲者: Sara A. Hurvitz, MD, FACP | West German Study Group and Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany and Department of Gynecology, University Medical Center Hamburg
摘要号：503
2596 例新辅助化疗治疗的淋巴结阳性乳腺癌患者中前哨淋巴结标记技术的比较：前瞻性多中心 AXSANA/EUBREAST-03/AGO-B-053研究（NCT04373655）结果
Comparison of marking techniques for target lymph nodes in 2,596 patients with node-positive breast cancer treated with neoadjuvant chemotherapy: Results from the prospective multicenter AXSANA/EUBREAST-03/AGO-B-053 study (NCT04373655).
讲者: Maggie Banys-Paluchowski, PhD | Department of Obstetrics and Gynecology, University Hospital of Schleswig Holstein, Campus Lübeck
摘要号：504
新辅助化疗后利用ctDNA 预测淋巴结负荷以进行手术规划：I-SPY2 试验结果
Predicting nodal burden after neoadjuvant chemotherapy (NAC) with circulating tumor (ct)DNA for surgical planning: Results from the I-SPY2 trial.
讲者: Rita Mukhtar, MD | Division of Surgical Oncology, Department of Surgery, University of California, San Francisco
摘要号：505
SOFT和TEXT试验15年随访结果：绝经前HR+早期乳腺癌患者辅助依西美坦+卵巢功能抑制对比他莫昔芬+卵巢功能抑制的长期获益
15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer (BC) in the SOFT and TEXT trials assessing benefits from adjuvant exemestane (E) + ovarian function suppression (OFS) or tamoxifen (T)+OFS.
讲者: Prudence A. Francis, MD, FRACP | Peter MacCallum Cancer Centre
摘要号：506
绝经前HR阳性乳腺癌女性卵巢功能抑制治疗生存结局更新及获益预测因素：ASTRRA 试验结果
Updated survival outcomes and predictors of benefit from ovarian function suppression in premenopausal women with hormone-receptor–positive breast cancer: Results from the ASTRRA trial.
讲者: Jai Min Ryu, MD, PhD | Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine
摘要号：507
卵巢功能抑制联合辅助内分泌治疗对年轻乳腺癌BRCA突变携带者生存结局的影响：一项国际队列研究的二次分析
The impact of ovarian function suppression with adjuvant endocrine therapy on survival outcomes in young germline BRCA mutation carriers with breast cancer: Secondary analysis of an international cohort study.
讲者: Paola Zagami, MD | UNC Lineberger Comprehensive Cancer Center/University of Milan/ European institute of Oncology IRCSS (IEO)
摘要号：508
Elinzanetant治疗辅助内分泌治疗相关血管舒缩症状的疗效和安全性：3 期 OASIS 4 试验
Efficacy and safety of elinzanetant for vasomotor symptoms associated with adjuvant endocrine therapy: Phase 3 OASIS 4 trial.
讲者: Fatima Cardoso, MD | ABC Global Alliance
Clinical Science Symposium
临床科学研讨会
专场时间：2025年6月1日 16:30 – 18:00
专场主席：Jo Chien, MD University of California, San Francisco Helen Diller Family Comprehensive Cancer Center；David W. Cescon, MD, PhD Princess Margaret Cancer Centre/UHN
专场地点：Arie Crown Theater | Live Stream
摘要号：1009
ctDNA与新辅助治疗后病理缓解及生存期的相关性：TBCRC 040（PREDICT-DNA试验）首次结果
Circulating tumor DNA, pathologic response after neoadjuvant therapy, and survival: First results from TBCRC 040 (the PREDICT-DNA trial).
讲者: Natasha Hunter, MD | University of Washington
摘要号：1010
ER+/HER2-高风险乳腺癌患者辅助内分泌治疗期间的ctDNA动态监测分析
Circulating tumor (ct)DNA monitoring of ER+/HER2- high-risk breast cancer during adjuvant endocrine therapy.
讲者: Lajos Pusztai, MD, PhD, FASCO, D.Phil | Yale Cancer Center, Yale School of Medicine
摘要号：1011
ctDNA动态变化作为转移性乳腺癌治疗反应预测指标的研究
Circulating tumor DNA (ctDNA) dynamics as a predictor of treatment response in metastatic breast cancer (mBC).
讲者: Pedram Razavi, MD, PhD | Memorial Sloan Kettering Cancer Center
摘要号：1012
SWOG S1416 试验中TNBC ctDNA体细胞同源重组缺陷（HRD）评估
Assessment of ctDNA somatic homologous recombination deficiency (HRD) in triple-negative breast cancer (TNBC) from SWOG S1416 trial.
讲者: Shane R. Stecklein, MD, PhD | University of Kansas Medical Center
Rapid Oral Abstract Session
中枢神经系统肿瘤——脑转移
Central Nervous System Tumors——Brain Metastases
专场时间：2025年5月31日 15:00 – 16:30
专场主席：Jennie Webster Taylor, MD, MPH
University of California San Francisco；Matthias Holdhoff, MD, PhD Johns Hopkins Medical Center
专场地点：S102 | On Demand
摘要号：2012
优替德隆联合依托泊苷和贝伐珠单抗治疗脑转移的HER2阴性乳腺癌症患者：一项前瞻性、单臂、II期试验
Utidelone in combination with etoposide and bevacizumab in HER2-negative breast cancer patients with brain metastasis: A prospective, single-arm, phase II trial.
讲者: 史业辉, MD, PhyD | 天津医科大学肿瘤医院
排版编辑：肿瘤资讯-张薪媛
苏公网安备32059002004080号
